<DOC>
	<DOCNO>NCT01096511</DOCNO>
	<brief_summary>This study local , prospective , open-label , company-sponsored , non interventional , multi-center study . Patients document must suffer cIAI take least one dose Moxifloxacin infusion.The primary objective define type cIAI infection require Moxifloxacin i.v . therapy China .</brief_summary>
	<brief_title>Moxifloxacin i.v . Treatment Complicated Intra-Abdominal Infection ( cIAI )</brief_title>
	<detailed_description />
	<mesh_term>Peritonitis</mesh_term>
	<mesh_term>Intraabdominal Infections</mesh_term>
	<mesh_term>Abdominal Abscess</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Patients least 18 year age diagnosis cIAI treat Moxifloxacin infusion with/without sequential tablet treatment include study . The local Moxifloxacin product information must consider . Contraindications state local Moxifloxacin product information . Warnings precaution , state local Moxifloxacin product information must consider potential exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Moxifloxacin ,</keyword>
	<keyword>cIAI</keyword>
	<keyword>non-interventional</keyword>
</DOC>